Alcon Stock

Alcon Equity

The The Equity of Alcon (ALC.SW) as of Jul 20, 2026 is 22.03 B USD. In the previous year, The Equity was 21.55 B USD — a change of 2.23% (higher).

Equity

22.03 BUSD

YoY

2.23%

Last updated:

In 2026, Alcon's equity was 22.03 B USD, a 2.23% increase from the 21.55 B USD equity in the previous year.

Access this data via the Eulerpool API

Alcon Stock analysis

What does Alcon do? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Alcon's Equity

Alcon's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Alcon's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Alcon's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Alcon's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Alcon’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Alcon stock

The Equity of Alcon is 22.03 B USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Alcon

All Key Metrics — Alcon